secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001104659-23-069993
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer terminates global license deal for Theravance's preclinical JAK inhibitor
--------------------------------------------------------------------------------

- Termination effective Oct 7, 2023; Pfizer gave notice June 9, 2023.
- Agreement covered preclinical skin-selective, locally acting pan-JAK inhibitor program.
- No reason for termination or financial impact disclosed by Theravance.
- Theravance regains rights to the program subject to wind-down obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/0001104659-23-069993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/tm2318324d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-069993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer